-
Presenter Profile: Roots of Inequity: In Utero Social and Environmental Impacts on Childhood Metabolic Risk
Izzuddin Aris, PhD, previews a presentation at the 2026 Scientific Sessions. Attendees in New Orleans can watch the session in-person Monday, June 8, at 8:00 a.m. CT.
-
Presenter Profile: Diabetes Devices: The Need for Waste Reduction
Lutz Heinemann, PhD, previews a presentation at the 2026 Scientific Sessions. Attendees in New Orleans can watch the session in-person Sunday, June 7, at 1:30 p.m. CT.
-
Presenter Profile: Do More Zzz’s Increase Time in Range in Youth with Type 1 Diabetes?
Sarah Jaser, PhD, previews a presentation at the 2026 Scientific Sessions. Attendees in New Orleans can watch the session in-person Saturday, June 6, at 1:30 p.m. CT.
-
Presenter Profile: CGM in Primary Care
Thomas Martens, MD, previews a presentation at the 2026 Scientific Sessions. Attendees in New Orleans can watch the session in-person Saturday, June 6, at 3:15 p.m. CT.
-
Presenter Profile: Advancing the Diabetic Eye Disease Care Continuum: Screening, Referral Pathways, Specialty Care, and Quality Outcomes
Caroline Presley, MD, MPH, previews a presentation at the 2026 Scientific Sessions. Attendees in New Orleans can watch the session in-person Friday, June 5, at 3:45 p.m. CT.
-
Presenter Profile: Pharmacotherapy Considerations
Elena Toschi, MD, previews a presentation at the 2026 Scientific Sessions. Attendees in New Orleans can watch the session in-person Friday, June 5, at 3:45 p.m. CT.
-
Presenter Profile: Next-Generation Pharmacotherapies to Reduce Hypoglycemia
Matthew J. Webber, PhD, previews a presentation at the 2026 Scientific Sessions. Attendees in New Orleans can watch the session in-person Sunday, June 7, at 1:30 p.m. CT.
-
Investigators to bring data on glucose management with oral orforglipron
Julio Rosenstock, MD, Francesco Giorgino, MD, PhD, and other panelists will discuss results from the ACHIEVE clinical trials, including ACHIEVE-3, which compared oral semaglutide and orforglipron for use in type 2 diabetes.
-
Researchers to share VESPER phase 2 clinical trial data
Investigators, including John B. Buse, MD, PhD, will discuss new insights from the VESPER program examining berobenatide, an ultra-long-acting glucagon-like peptide-1 (GLP-1) receptor agonist for weight management.
-
Experts to discuss the benefits of glucagon/GLP-1 receptor dual agonism gleaned from SYNCHRONIZE
Lee Kaplan, MD, PhD, and other investigators will examine the basic science underlying injectable survodutide, as well as results from two of the four studies in the SYNCHRONIZE program.